Santhera Pharmaceuticals Holding AG (0QN1.L)
CHF 9.79
(-0.81%)
CHF 9.79
(-0.81%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 99.54 Million CHF | 2463.93% |
| 2022 | 3.88 Million CHF | 172.38% |
| 2021 | -5.36 Million CHF | -217.15% |
| 2020 | 4.57 Million CHF | -93.45% |
| 2019 | 69.92 Million CHF | 159.42% |
| 2018 | 26.95 Million CHF | 43.08% |
| 2017 | 18.83 Million CHF | 24.35% |
| 2016 | 15.15 Million CHF | 413.56% |
| 2015 | 2.95 Million CHF | 23.33% |
| 2014 | 2.39 Million CHF | 102.88% |
| 2013 | 1.17 Million CHF | -63.03% |
| 2012 | 3.18 Million CHF | 8.95% |
| 2011 | 2.92 Million CHF | -85.53% |
| 2010 | 20.23 Million CHF | 1346.1% |
| 2009 | 1.39 Million CHF | 5496.0% |
| 2008 | 25 Thousand CHF | -99.73% |
| 2007 | 9.22 Million CHF | 1081.31% |
| 2006 | 781 Thousand CHF | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 4.44 Million CHF | 158.6% |
| 2024 Q1 | 4.44 Million CHF | -95.45% |
| 2023 Q2 | 1.7 Million CHF | 69.57% |
| 2023 Q4 | 97.8 Million CHF | 99.33% |
| 2023 FY | 99.5 Million CHF | 2463.93% |
| 2023 Q1 | 1 Million CHF | 224.91% |
| 2023 Q3 | 49.06 Million CHF | 2777.71% |
| 2022 Q3 | -247 Thousand CHF | -106.06% |
| 2022 Q1 | 2.18 Million CHF | 126.9% |
| 2022 Q2 | 4.07 Million CHF | 86.42% |
| 2022 FY | 3.88 Million CHF | 172.38% |
| 2022 Q4 | -805 Thousand CHF | -225.91% |
| 2021 Q2 | 2.08 Million CHF | 69.61% |
| 2021 Q4 | -8.13 Million CHF | -107.93% |
| 2021 FY | -5.36 Million CHF | -217.15% |
| 2021 Q3 | -3.91 Million CHF | -287.42% |
| 2021 Q1 | 1.23 Million CHF | 128.32% |
| 2020 Q2 | 4.82 Million CHF | 70.43% |
| 2020 Q1 | 2.83 Million CHF | -94.69% |
| 2020 Q4 | -4.34 Million CHF | -701.66% |
| 2020 Q3 | -542 Thousand CHF | -111.24% |
| 2020 FY | 4.57 Million CHF | -93.45% |
| 2019 Q4 | 53.29 Million CHF | 96.78% |
| 2019 Q2 | 14.89 Million CHF | 89.07% |
| 2019 FY | 69.92 Million CHF | 159.42% |
| 2019 Q1 | 7.87 Million CHF | 13.74% |
| 2019 Q3 | 27.08 Million CHF | 81.81% |
| 2018 Q4 | 6.92 Million CHF | 7.55% |
| 2018 Q3 | 6.44 Million CHF | -5.18% |
| 2018 Q1 | 6.79 Million CHF | 23.06% |
| 2018 FY | 26.95 Million CHF | 43.08% |
| 2018 Q2 | 6.79 Million CHF | 0.0% |
| 2017 Q1 | 4.45 Million CHF | -9.6% |
| 2017 FY | 18.83 Million CHF | 24.35% |
| 2017 Q2 | 4.45 Million CHF | 0.0% |
| 2017 Q4 | 5.52 Million CHF | 25.06% |
| 2017 Q3 | 4.41 Million CHF | -0.86% |
| 2016 Q4 | 4.92 Million CHF | 0.0% |
| 2016 Q2 | 2.64 Million CHF | 0.0% |
| 2016 Q3 | 4.92 Million CHF | 85.9% |
| 2016 FY | 15.15 Million CHF | 413.56% |
| 2016 Q1 | 2.64 Million CHF | 220.37% |
| 2015 FY | 2.95 Million CHF | 23.33% |
| 2015 Q2 | 648 Thousand CHF | 0.0% |
| 2015 Q1 | 648 Thousand CHF | -20.88% |
| 2015 Q4 | 827 Thousand CHF | 0.0% |
| 2015 Q3 | 827 Thousand CHF | 27.62% |
| 2014 Q1 | 377 Thousand CHF | 321.23% |
| 2014 FY | 2.39 Million CHF | 102.88% |
| 2014 Q2 | 377 Thousand CHF | 0.0% |
| 2014 Q4 | 819 Thousand CHF | 0.0% |
| 2014 Q3 | 819 Thousand CHF | 117.24% |
| 2013 Q1 | 500 Thousand CHF | 255.52% |
| 2013 Q4 | 89.5 Thousand CHF | 0.0% |
| 2013 FY | 1.17 Million CHF | -63.03% |
| 2013 Q2 | 500 Thousand CHF | 0.0% |
| 2013 Q3 | 89.5 Thousand CHF | -82.1% |
| 2012 Q3 | -321.5 Thousand CHF | 0.0% |
| 2012 FY | 3.18 Million CHF | 8.95% |
| 2012 Q4 | -321.5 Thousand CHF | 0.0% |
| 2011 FY | 2.92 Million CHF | -85.53% |
| 2010 FY | 20.23 Million CHF | 1346.1% |
| 2009 FY | 1.39 Million CHF | 5496.0% |
| 2008 FY | 25 Thousand CHF | -99.73% |
| 2007 FY | 9.22 Million CHF | 1081.31% |
| 2006 FY | 781 Thousand CHF | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Relief Therapeutics Holding AG | -10.85 Million CHF | 1016.696% |
| Tecan Group AG | 390.46 Million CHF | 74.506% |
| Basilea Pharmaceutica AG | 130.84 Million CHF | 23.919% |
| Bachem Holding AG | 176.96 Million CHF | 43.749% |
| Siegfried Holding AG | 320.4 Million CHF | 68.932% |
| Molecular Partners AG | -40.8 Million CHF | 343.945% |